赛立奇单抗治疗重度斑块状银屑病的短期疗效与安全性:一项基于真实世界数据的回顾性分析OA
Short-term efficacy and safety of xeligekimab in severe plaque psoriasis:A retrospective re-al-world study
目的 基于真实世界数据,观察赛立奇单抗治疗重度斑块状银屑病患者的短期疗效与安全性,并与同期使用司库奇尤单抗的患者进行探索性对比观察.方法 回顾性分析 2024 年 9 月至 2025年12 月于开封市人民医院皮肤科就诊的重度斑块状银屑病患者的临床资料.赛立奇单抗组纳入 23例,并从同期 52 例接受司库奇尤单抗治疗的患者中采用倾向性评分匹配筛选 23 例(卡钳值=0.02).两组共46 例纳入最终分析,比较两组患者治疗前及治疗 4、12 周后的银屑病面积与严重程度指数(PASI)评分及 PASI 75/90/100 应答率,记录治疗 12 周后的研究者总体评估(IGA)评分及不良反应.结果 匹配后两组基线资料差异无统计学意义(均 P>0.05).治疗 4 周及 12 周后,两组 PASI 评分均较治疗前显著降低(赛立奇单抗组:治疗4 周,t=20.75,治疗 12 周,t=24.23;司库奇尤单抗组:治疗 4周,t=20.85,治疗12 周,t=23.01,均 P<0.001).治疗 12 周后,两组 IGA 评分均较治疗前显著下降(赛立奇单抗组:Z=-4.28,司库奇尤单抗组,Z=-4.26,均 P<0.001).治疗 4 周及 12 周后,两组PASI 75、PASI 90、PASI 100 应答率差异均无统计学意义(均 P>0.05).两组不良反应总发生率分别为8.70%(2/23)和13.04%(3/23),差异无统计学意义(P=1.000).结论 赛立奇单抗治疗重度斑块状银屑病显示出良好的短期疗效和可接受的安全性,司库奇尤单抗组亦观察到一致的疗效改善趋势,但本研究为非随机探索性分析,上述结果尚需进一步验证.
Objective To evaluate the short-term efficacy and safety of xeligekimab in patients with severe plaque psoriasis based on real-world data,and to perform an exploratory comparison with patients treated with secukinumab during the same period.Methods The clinical data of eli-gible patients with severe plaque psoriasis treated at the Department of Dermatology,Kaifeng Peo-ple's Hospital,between September 2024 and December 2025 were retrospectively analyzed.The xeligekimab group included 23 patients,while the control group comprised 23 patients selected from 52 patients who received secukinumab during the same period using propensity score matc-hing with a caliper value of 0.02.A total of 46 patients were included in the final analysis.The psoriasis area and severity index(PASI)scores and PASI 75/90/100 response rates were com-pared between the groups at baseline and at weeks 4 and 12.Investigator global assessment(IGA)scores and adverse reactions were also recorded.Results After matching,baseline char-acteristics showed no statistically significant differences between the two groups(all P values>0.05).At weeks 4 and 12,PASI scores decreased significantly compared with baseline in both groups(xeligekimab group:t=20.75 and 24.23,respectively;secukinumab:t=20.85 and 23.01,respectively;all P<0.001).IGA scores also decreased significantly at week 12 in both groups(xeligekimab:Z=-4.28;secukinumab:Z=-4.26;both P<0.001).No significant between-group differences were observed in PASI 75/90/100 response rates at weeks 4 and 12(all P values>0.05).The overall incidence of adverse events was 8.70%(2/23)in the xe-ligekimab group and 13.04%(3/23)in the secukinumab group,with no statistically significant difference(P=1.000).Conclusions Xeligekimab showed favorable short-term efficacy and ac-ceptable safety in the treatment of severe plaque psoriasis.The secukinumab reference group showed a similar pattern of clinical improvement.However,given the non-randomized,exploratory nature of this study,these findings warrant further validation in prospective studies.
张文文;靳旺洋;蔡璐璐;顿耿
开封市人民医院,河南 开封 475000开封市人民医院,河南 开封 475000开封市人民医院,河南 开封 475000开封市人民医院,河南 开封 475000
银屑病赛立奇单抗司库奇尤单抗临床疗效安全性
psoriasisxeligekimabsecukinumabclinical efficacysafety
《皮肤性病诊疗学杂志》 2026 (8)
580-585,6
开封市科技发展计划项目(2307009)
评论